<DOC>
	<DOCNO>NCT00085202</DOCNO>
	<brief_summary>Drugs use chemotherapy , vincristine , cisplatin , cyclophosphamide , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . Autologous stem cell transplant may able replace blood-forming cell destroy chemotherapy radiation therapy . It yet know radiation therapy regimen combine chemotherapy donor stem cell transplant effective treating medulloblastoma , supratentorial primitive neuroectodermal tumor , atypical teratoid rhabdoid tumor . This phase III trial study two different regimen radiation therapy give together chemotherapy autologous stem cell transplant see well work treat patient newly diagnose medulloblastoma , supratentorial primitive neuroectodermal tumor , atypical teratoid rhabdoid tumor . PRIMARY OBJECTIVE : - To assess relationship ERBB2 protein expression tumor progression-free survival probability patient medulloblastoma . - To estimate frequency mutation associate SHH WNT tumor ( define gene expression profile ) via target sequencing perform independent cohort WNT SHH tumor ( also define gene expression profile ) .</brief_summary>
	<brief_title>Treatment Patients With Newly Diagnosed Medulloblastoma , Supratentorial Primitive Neuroectodermal Tumor , Atypical Teratoid Rhabdoid Tumor</brief_title>
	<detailed_description>SECONDARY OBJECTIVES : - To compare effect computer-based training system specifically target language , reading , learn skill ( Fast ForWord , Scientific Learning Corporation ) current standard care read decode skill measure individual academic testing . - To monitor treatment failure posterior fossa patient whose tumor bed receives reduce volume radiation . - To correlate radiation dosimetry target normal tissue rate pattern failure longitudinal measure audiometric , endocrine cognitive effect . EXPLORATORY OBJECTIVES : - To estimate change neuropsychological performance neuropsychology assessment battery ( intellect , academic achievement cognitive ability ) examine relationship change risk group , age diagnosis , parent measure . - To evaluate difference neurotoxicity average-risk patient group high-risk group qMRI , fMRI . - To develop refine novel model relate impact medulloblastoma therapy neurocognitive performance quantitative functional neuroimaging measure . OUTLINE : This multicenter study . Patients stratify accord disease risk ( high-risk disease v average-risk disease ) . Patients strata undergo peripheral blood stem cell bone marrow harvest . - Stratum 1 ( high-risk group ) : - Radiotherapy : Patients undergo craniospinal radiotherapy daily 5 day week 6 week . - High-dose chemotherapy autologous stem cell transplantation ( SCT ) : Six week completion radiotherapy , patient receive high-dose chemotherapy comprise vincristine IV follow cisplatin IV 6 hour day -4 cyclophosphamide IV 1 hour day -3 -2 . Patients undergo autologous SCT day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 1 continue blood count recover . Patients receive vincristine IV day 6 . High-dose chemotherapy autologous SCT repeat every 4 week 3 additional course absence unacceptable toxicity . - Stratum 2 ( average-risk group ) : - Radiotherapy : Patients undergo craniospinal radiotherapy stratum 1 , low dose . - High-dose chemotherapy autologous SCT : Patients receive high-dose chemotherapy , autologous SCT , G-CSF , post-transplantation vincristine stratum 1 . Some patient undergo neuropsychology assessment baseline , chemotherapy , annually 5 year . After completion study therapy , patient follow every 3 month month 30 ( 2.5 year ) diagnosis every 6 month month 72 ( 6 year ) diagnosis .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Teratoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Medulloblastoma Supratentorial primitive neuroectodermal tumor ( PNET ) PNET variant ( ependymoblastoma , pineoblastoma , CNS neuroblastoma ) Atypical teratoid rhabdoid tumor ( ATRT ) Definitive surgery CNS tumor within past 31 day Meets one follow risk criterion : Averagerisk disease Localized disease overt evidence invasion beyond posterior fossa ( supratentorial compartment PNET ATRT ) intraoperative observation neurosurgeon AND postoperative CT scan MRI T4 disease eligible follow true : Gross total resection determine intraoperative observation neurosurgeon AND postoperative CT scan MRI Residual tumor image abnormality whose size &lt; 1.5 cm^2 No evidence CNS extraneural metastasis MRI spine ( without contrast agent ) CTbased myelogram AND cytologic examination lumbar cerebral spinal fluid ( CSF ) 1428 day surgery Brain stem invasion allow absence residual tumor ( tumor &lt; 1.5 cm^2 image ) Highrisk disease meet one follow criterion : Metastatic disease within neuraxis ( i.e. , evidence subarachnoid dissemination image and/or cytologic examination CSF ) Presence residual disease &gt; 1.5 cm^2 primary site surgery PATIENT CHARACTERISTICS : Age 3 21 diagnosis Performance status Lansky 30100 % ( &lt; 10 year old ) Karnofsky 30100 % ( â‰¥ 10 year old ) ( except posterior fossa syndrome ) Life expectancy Not specify Hematopoietic Hemoglobin &gt; 8 g/dL WBC &gt; 2,000/mm^3 Absolute neutrophil count &gt; 500/mm^3 Platelet count &gt; 50,000/mm^3 Hepatic ALT &lt; 5 time normal Bilirubin &lt; 3.0 mg/dL Renal Creatinine &lt; 2.0 mg/dL OR Creatinine clearance &gt; 70 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Prior corticosteroid therapy allow Radiotherapy No prior radiotherapy Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>untreated childhood pineoblastoma</keyword>
</DOC>